Galapagos Expands Merck Drug Target Pact | GenomeWeb

NEW YORK (GenomeWeb News) – Galapagos said today that it has expanded a preclinical development agreement to discover, screen, and validate drug targets that Merck will develop and take to market.

The agreement, which could be worth as much as €400 million ($596 million), adds atherosclerosis drug targets to an earlier one that covered targets for obesity and diabetes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene flow between ancient chimpanzees and bonobos, and more.

A startup wants to match customers to wine based on their DNA and one critic calls the idea 'silly,' Stat News reports.

Researchers trace the origins of brown rats using genetic analysis to China, the New York Times reports.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.